Pipeline Flex Embolization Device Clinical Study

  • Research type

    Research Study

  • Full title

    Pipeline Flex Embolization Device Clinical Study

  • IRAS ID

    156617

  • Contact name

    Saleh Lamin

  • Contact email

    saleh.lamin@uhb.nhs.uk

  • Sponsor organisation

    Covidien

  • Duration of Study in the UK

    0 years, 7 months, 30 days

  • Research summary

    The Pipeline Flex Embolization (PFED) device is a commercially available flow diversion device used for the treatment of cerebral aneurysms. The purpose of this post-market study is to assess the acute technical device deployment success rate and safety of PFED in a clinical setting. In addition to deployment success, safety will be assessed based on occurrence of major stroke or neurological death at 30 days post-procedure due to complications related to the PFED. Similarly, device resheathability and redeployment success and other neurological safety events will be assessed.

    The first generation Pipeline Embolization device has a technical success rate of 87-100%. The PFED has a new delivery system that allows the physician to reposition and redeploy the device. Although the new PFED device is commercially available, Covidien would like to build upon its body of evidence regarding the technical success rate of the PFED as well as its safety profile.

    The duration of the PFLEX study will be approximately 8 months. There will be up to 10 participating centers. To participate in the study, the subject must have already been selected for flow diversion therapy as the appropriate treatment and must meet all inclusion and exclusion criteria as outlined in the protocol. Furthermore, the PFED must be used according to the indication within the approved labelling of the device. Information will be collected for up to 50 deployments of the device in up to 50 subjects across the centers. There will be a follow-up period of 30 days for each enrolled subject. Information pertaining to subject demographics, medical history, pertinent medications, aneurysm characteristics collected from imaging along with any reported adverse events will be collected for each subject enrolled. The information collected will be analysed to determine the technical success rate and review the safety profile of the PFED.

  • REC name

    South Central - Oxford B Research Ethics Committee

  • REC reference

    14/SC/1307

  • Date of REC Opinion

    16 Oct 2014

  • REC opinion

    Further Information Favourable Opinion